Clarametyx Biosciences, Inc.
Clarametyx Biosciences is a biotechnology company focused on developing immune-enabling therapies and vaccines to combat persistent bacterial infections associated with biofilms. They are pioneering innovative solutions to address the global challenge of antibiotic resistance and biofilm-related infections, with a pipeline that includes antibody therapies and vaccines targeting bacterial biofilms.
Industries
Nr. of Employees
small (1-50)
Clarametyx Biosciences, Inc.
Products
Immune-enabling monoclonal antibody candidate (lead)
A humanized monoclonal antibody therapeutic designed to rapidly disrupt bacterial biofilm structure and sensitize pathogens to antibiotic and innate immune clearance; developed for severe respiratory infections and tested in early-phase clinical trials.
Anti-biofilm vaccine candidate (preventative)
A vaccine program designed to prevent biofilm formation and maturation by targeting conserved biofilm structural elements, advanced through lead optimization toward IND-enabling studies and Phase 1 evaluation.
Immune-enabling monoclonal antibody candidate (lead)
A humanized monoclonal antibody therapeutic designed to rapidly disrupt bacterial biofilm structure and sensitize pathogens to antibiotic and innate immune clearance; developed for severe respiratory infections and tested in early-phase clinical trials.
Anti-biofilm vaccine candidate (preventative)
A vaccine program designed to prevent biofilm formation and maturation by targeting conserved biofilm structural elements, advanced through lead optimization toward IND-enabling studies and Phase 1 evaluation.
Services
Lead optimization, mechanism-of-action studies, and IND-enabling preclinical work to advance therapeutics and preventative candidates targeting bacterial biofilms.
Design and conduct of early-stage clinical trials including randomized, placebo-controlled studies with safety, PK, immunogenicity and exploratory efficacy endpoints.
Lead optimization, mechanism-of-action studies, and IND-enabling preclinical work to advance therapeutics and preventative candidates targeting bacterial biofilms.
Design and conduct of early-stage clinical trials including randomized, placebo-controlled studies with safety, PK, immunogenicity and exploratory efficacy endpoints.
Expertise Areas
- Biofilm-targeted therapeutics
- Monoclonal antibody development (humanized biologics)
- Anti-biofilm vaccine development
- Preclinical-to-IND translational development
Key Technologies
- Biofilm matrix-targeting biologics
- Monoclonal antibody engineering and humanization
- Vaccine antigen design for biofilm prevention
- Preclinical efficacy models for biofilm-associated infections